Literature DB >> 23784770

Dabigatran, electrical cardioversion and measuring the aPTT. A safety measure or an unnecessary assessment?

N Rahmat1, A Khan.   

Abstract

We present two case reports of patients treated with dabigatran for stroke prevention. Both have non-valvular atrial fibrillation and both were scheduled for direct current electrical cardioversion (DCCV). Both had their activated partial thromboplastin time (aPTT) measured prior to their DCCV to assess the anticoagulant activity of dabigatran. The decision to measure the aPTT resulted in differing levels to otherwise straightforward cases.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23784770      PMCID： PMC3702943          DOI： 10.1136/bcr-2013-010090

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  15 in total

1.  Heparin resistance.

Authors:  J A M Anderson; E L Saenko
Journal:  Br J Anaesth       Date:  2002-04       Impact factor: 9.166

Review 2.  Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis.

Authors:  Birgitta Salmela; Lotta Joutsi-Korhonen; Elina Armstrong; Riitta Lassila
Journal:  Semin Thromb Hemost       Date:  2012-02-07       Impact factor: 4.180

3.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

4.  Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.

Authors:  Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2011-01-03       Impact factor: 29.690

5.  The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation.

Authors:  C J Bjerkelund; O M Orning
Journal:  Am J Cardiol       Date:  1969-02       Impact factor: 2.778

6.  Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study.

Authors:  William E Dager; Robert C Gosselin; Steve Kitchen; Dennis Dwyre
Journal:  Ann Pharmacother       Date:  2012-12-11       Impact factor: 3.154

7.  Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.

Authors:  Shinya Suzuki; Takayuki Otsuka; Koichi Sagara; Shunsuke Matsuno; Ryuichi Funada; Tokuhisa Uejima; Yuji Oikawa; Junji Yajima; Akira Koike; Kazuyuki Nagashima; Hajime Kirigaya; Hitoshi Sawada; Tadanori Aizawa; Takeshi Yamashita
Journal:  Circ J       Date:  2012-01-31       Impact factor: 2.993

Review 8.  Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

Authors:  Marta A Miyares; Kyle Davis
Journal:  Am J Health Syst Pharm       Date:  2012-09-01       Impact factor: 2.637

9.  Dabigatran etexilate: management in acute ischemic stroke.

Authors:  Parisa P Javedani; B Zane Horowitz; Wayne M Clark; Helmi L Lutsep
Journal:  Am J Crit Care       Date:  2013-03       Impact factor: 2.228

Review 10.  An algorithm for managing warfarin resistance.

Authors:  Olusegun Osinbowale; Monzr Al Malki; Andrew Schade; John R Bartholomew
Journal:  Cleve Clin J Med       Date:  2009-12       Impact factor: 2.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.